Description of Patients With Type 1 Diabetes Treated With Teplizumab
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
110actual
Sites
27
Countries
Israel, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-11 | actual | When the study began enrolling |
| Primary completion | 2025-08-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-05 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 1 Diabetes
Intervention
- Drug: Teplizumab
Primary outcomes
what the primary-completion date above is the date OFParticipant demographic characteristics at teplizumab initiation
measured At Day 1 (first dose of teplizumab)
Participants' family history of T1D and autoimmune diseases
measured At Day 1 (first dose of teplizumab)
Presence of T1D susceptibility genes: Genetic risk score
measured At Day 1 (first dose of teplizumab)
Presence of T1D susceptibility genes: Human Leukocyte Antigen (HLA)-haplotype
measured At Day 1 (first dose of teplizumab)
Participants' medical history
measured From 6 months prior to the first dose of teplizumab (teplizumab initiation) (or the earliest date of all data contributing to Stage 2 T1D diagnosis, whichever is earlier) up to the medical records abstraction date, approximately 3-4 years
Assessment of blood glucose test results: CGM
measured At screening (6 months before teplizumab initiation), within 6 weeks prior to teplizumab initiation, during teplizumab infusion (2 weeks), following completion of teplizumab treatment (through study completion, up to 30 months)"
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed